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Abstract
Introduction: Myositis specific autoantibodies are associated with unique clinical subsets and are useful biomarkers
in polymyositis/dermatomyositis (PM/DM). A 120 kD protein recognized by certain patients with DM was identified
and clinical features of patients with this specificity were characterized.
Methods: The 120 kD protein recognized by a prototype serum was purified and identified by mass spectrometry
and immunological methods. Autoantibody to this 120 kD protein was screened in sera from 2,356 patients with
various diagnoses from four countries, including 254 PM/DM, by immunoprecipitation of 35S-methionine labeled
K562 cell extracts. Clinical information of patients with this specificity was collected.
Results: The 120 kD protein, which exactly comigrated with PL-12, was identified as transcription intermediary
factor TIF1b (TRIM28) by mass spectrometry and validated by immunoassays. By immunofluorescence, anti-TIF1b
positivity showed a fine-speckled nuclear staining pattern. Four cases of anti-TIF1b were identified; all are women,
one each in a Japanese, African American, Caucasian, and Mexican individual. Three had a diagnosis of DM and
one case was classified as having an undifferentiated connective tissue disease with an elevated CPK but without
significant muscle symptoms. This individual also had a history of colon cancer, cervical squamous metaplasia and
fibroid tumors of the uterus. Myopathy was mild in all cases and resolved without treatment in one case. The anti-
TIF1b specificity was not found in other conditions.
Conclusions: Anti-TIF1b is a new DM autoantibody associated with a mild form of myopathy. Whether it has an
association with malignancy, as in the case of anti-TIF1g, or other unique features will need to be evaluated in
future studies.
Introduction
Autoantibodies to cellular constituents are clinically
important biomarkers associated with particular diagnoses,
specific clinical features or subsets of disease, helping to
establish a diagnosis, and/or predicting organ involvement
and prognosis [1,2]. In particular, in polymyositis/derma-
tomyositis (PM/DM) and scleroderma (systemic sclerosis,
SSc) patients can be classified into several subsets asso-
ciated with characteristic clinical features based on specific
autoantibodies, since coexistence of other disease-specific
autoantibodies is uncommon [3]. Each myositis specific
antibody (MSA) is associated with a unique clinical subset.
For example, the anti-synthetase syndrome was named for
the presence of anti-Jo-1 and other autoantibodies to ami-
noacyl tRNA synthetases found in a subset of patients
with PM/DM whose clinical presentation was dominated
by interstitial lung disease (ILD), Raynaud’s phenomenon,
arthritis, fever, and mechanic’s hands [3,4]. Although new
autoantibody specificities have been reported, approxi-
mately 40% to 50% of patients with PM/DM are still with-
out a known MSA compared with only approximately
15% in SSc without association to known SSc antibodies
[2]. Thus, identifying new MSA may help in monitoring
PM/DM patients and several new clinically significant
autoantibodies associated with DM including anti-p155/
140 [5-11], anti-CADM (clinically amyopathic DM) 140/
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MDA5 (melanoma differentiation associated antigen 5)
[10,12-14], anti-SAE (small ubiquitin-like molecule activat-
ing enzyme) and anti-MJ/NXP-2 have been reported
recently [15,16]. Among these, anti-p155/140 has been
studied extensively in a very short period of time due to its
strong association with malignancy [5-9,11] which was
confirmed by a recent meta-analysis [17]. However, this
association does not appear to apply to children [7] or
young adults [11]. p155 was identified as transcription
intermediary factor1g, (TIF1g, also known as tripartite
motif (TRIM) 33) [18]. A recent study in Japanese patients
has identified the p140 as TIF1a and another related
molecule TIF1b has also been identified as a target of
autoantibodies in DM [11]. In the present study, we have
independently identified the approximately 120 kD auto-
antigenic protein as TIF1b by mass spectrometry. The pre-
sence of anti-TIF1b and clinical features of American,
Mexican, and Japanese patients with this specificity were
characterized.
Materials and methods
Patients
A total of 2,356 sera, including 1,966 subjects enrolled in
the University of Florida Center for Autoimmune
Diseases (UFCAD) registry from 2000 to 2010, were stu-
died. Diagnoses of the UFCAD patients include 434 sys-
temic lupus erythematosus (SLE), 86 PM/DM (51 PM
including 12 PM-SSc overlap, 35 DM), 121 SSc, and 122
rheumatoid arthritis (RA). Additionally, sera from
36 PM/DM (13 PM, 20 DM, 3 amyopathic DM) from St.
Marianna University Hospital (Kawasaki, Japan), 74 PM/
DM (18 PM, 56 DM) sera from Guadalajara and Mexico
City (Mexico), 58 PM/DM (25 PM, 27 DM, 6 overlap:
4 PM-SSc, 1 DM-SLE, 1 PM-RA), 57 SSc, and 113 SLE,
and 52 primary anti-phospholipid syndrome (PAPS) from
Spedali Civili di Brescia (Brescia, Italy) were also
screened. Diagnosis of PM/DM is by physician’s assess-
ment based on Bohan’s criteria (PM/DM). Other diag-
noses were established by the American College of
Rheumatology (ACR) (SLE, SSc, RA) or European criteria
(Sjögren’s syndrome). Clinical information was from
database and medical records. The protocol was
approved by the Institutional Review Board (IRB). This
study meets and is in compliance with all ethical stan-
dards in medicine, and informed consent was obtained
from all patients according to the Declaration of Helsinki.
Materials and methods
Immunoprecipitation
Autoantibodies in sera were screened by immunoprecipi-
tation using 35S-methionine labeled K562 cell extracts
[19]. Specificity of autoantibodies was determined using
previously described reference sera. Analysis of RNA com-
ponents of autoantigens was by urea-PAGE and silver
staining (Silver Stain Plus, Bio-Rad, Hercules, CA, USA)
[20].
Identification of proteins by LC-MS/MS
The new unidentified autoantigen of 120 kD protein was
purified using serum from the prototype patient. Immuno-
globulin G (IgG) from 20 μl of serum was crosslinked to
protein A Sepharose beads using dimethylpimerimidate.
Protein was then affinity-purified from a cell extract of 4 ×
108 K562 cells and fractionated by SDS-PAGE. The
120 kD protein band was cut following silver staining of
the gel, trypsin-digested and analyzed by liquid chromato-
graphy - tandem mass spectrometry (LC-MS/MS) analysis
on a hybrid quadrupole-TOF mass spectrometer (QSTAR
elite, Applied Biosystems) at UF ICBR Protein Core. Tan-
dem mass spectra were extracted by ABI Analyst version
2.0. All MS/MS samples were analyzed using Mascot
(Matrix Science, London, UK; version 2.2.2). Scaffold (ver-
sion Scaffold-02-03-01, Proteome Software Inc.) was used
to validate MS/MS based peptide (> 95.0% probability)
and protein identifications (> 99.0% probability and at
least two identified unique peptides).
Affinity purification of the TIF1b and western blot
Identity of the approximately 120 kD protein as TIF1b was
verified by immunoprecipitation followed by western blot
(IP-WB) using an extract from 5 × 106 K562 cells and 2 μl
of human serum. Purified proteins were fractionated in 8%
acrylamide SDS-PAGE, transferred to nitrocellulose filter
and probed with mouse anti-TIF1b monoclonal antibodies
(mAb) (EMD Millipore, Billerica, MA, USA), followed by
horseradish peroxidase-conjugated (HRP) goat anti-mouse
Ig light-chain antibodies (Jackson ImmunoResearch
Laboratories, Inc. West Grove, PA, USA) and developed
with SuperSignal West Femto Chemiluminescent Sub-
strate (Thermo Scientific, Rockford, IL, USA).
In another experiment, TIF1b was affinity purified
from an extract of 2 × 108 K562 cells using 10 μg of anti-
TIF1b mAb, and purified proteins were fractionated by
SDS-PAGE and transferred to nitrocellulose filter. Strips
(2 mm width) of nitrocellulose filter were probed with
mouse mAb and human autoimmune sera. Strips incu-
bated with mouse mAb were then incubated with HRP
goat anti-mouse Ig light-chain antibodies and developed,
while samples probed with human sera were incubated
with HRP-donkey IgG F(ab)’2 anti-human IgG (g-chain
specific) antibodies (Jackson ImmunoResearch Labora-
tories, Inc.) and developed.
Immunofluorescent antinuclear antibodies
Immunofluorescent antinuclear/cytoplasmic antibodies
(HEp-2 ANA slides; INOVA Diagnostics, San Diego, CA,
USA) were tested using a 1:80-diluted human serum or
2 μg/ml mouse mAb to TIF1b. Secondary antibodies were
DyLight 488 donkey IgG F(ab)’2 anti-human or -mouse
IgG (1:200 dilution, g-chain-specific, Jackson ImmunoRe-
search Laboratories).
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ELISA
Antigen-capture ELISA for anti-TIF1b was performed
using 2 μg/ml mouse mAb to TIF1b (Millipore), following
a protocol that was used for other autoantibody systems
[21]. Antibodies to TIF1a (p140 of p155/140), TIF1b, and
TIF1g (p155) were also tested using full-length recombi-
nant proteins from Abnova (TIF1a and b, Taipei, Taiwan)
and OriGene Technologies (TIF1g, Rockville, MD, USA),
respectively. Wells of microtiter plates were coated using
0.5 μg/ml of protein and ELISA was performed following
standard protocol as described [22].
Results
First, the 120 kD protein was affinity purified using the
human prototype serum and the identity of the protein
was determined by LC-MS/MS. Sixteen unique (total of
18) peptides that contained sequences identical to TIF1b
were isolated as follows: aa128-136 DIVENYFMR (n = 2),
aa254-261 KLLASLVK, aa283-290 QVSDVQKR, aa297-
304 MAILQIMK, aa310-319 GRVLVNDAQK, aa312-319
VLVNDAQK, aa312-327 VLVNDAQKVTEGQQER,
aa331-337 QHWTMTK, aa408-427 IVAERPGTNSTG-
PAPMAPPR, aa473-483 SGEGEVSGLMR (n = 2), aa493-
507 LDLDLTADSQPPVFK, aa508-524 VFPGSTTEDYN-
LIVIER, aa751-767 LSPPYSSPQEFAQDVGR, aa775-790
LTEDKADVQSIIGLQR, aa 780-790 ADVQSIIGLQR, and
aa796-804 MNEAFGDTK. These peptides covered 19.5%
(163/835 amino acids) of the sequence of TIF1b. Since the
reported molecular weight of TIF1b is approximately 120
kD, it was considered a good candidate and its identity
was validated using mAb to TIF1b.
Immunoprecipitation
The 120 kD proteins immunoprecipitated by four sera
(Figure 1A, lanes 1-4), both in size and appearance,
appeared identical to the TIF1b protein immunoprecipi-
tated by the mAb, consistent with the identity of the
120 kD proteins as TIF1b. TIF1b showed a migration pat-
tern similar to the known myositis autoantigen PL-12 but
had a broader band in contrast to the sharp band of PL-12
(Figure 1A). Two sera (lanes 1-2) had strong reactivity,
while the other two (lanes 3-4) were weak. When 20% of
the sample of case two was run (lane 2), it showed an
appearance that was very similar to the weak ones in lanes
3-4, suggesting that they are the same proteins. Although
TIF1b/TRIM28 and TIF1g/TRIM33 are in the same family
of related proteins and their interactions have been
reported [23], anti-TIF1b mAb did not immunoprecipitate
TIF1g/p155 (Figure 1A, lane TIF1b mAb). Also, anti-
TIF1g (p155/140) positive serum did not immunoprecipi-
tate TIF1b (Figure 1A, lane p155/140), consistent with a
lack of crossreactivity and interactions between TIF1b and
TIF1g under the conditions used for immunoprecipitation.
None of these four human sera with anti-TIF1b antibodies
clearly immunoprecipitated TIF1g/a (p155/140) (Figure
1A). However, the serum from case three was positive for
anti-TIF1a by ELISA using recombinant protein (Table 1).
Case four was negative for antibodies to ecombinant TIF1g
and a by ELISA. Also, none of the 23 anti-p155/140 posi-
tive sera in our cohort immunoprecipitated TIF1b (data
not shown). Case four had coexisting anti-Mi-2 antibodies
(Figure 1A, lane Mi-2), cases two and four had anti-Su/
Ago2, and case two also had anti-Ro and U1RNP. Sequen-
tial serum samples available for case two were tested by
immunoprecipitation (Figure 1B). The levels of anti-
U1RNP antibodies that were weakly positive at the initial
visit increased followed by the development of additional
autoantibodies to an unidentified protein of approximately
160 kD (white arrowhead).
Since many autoantigens in PM/DM are RNA-protein
complexes, RNA components in immunoprecipitates were
also analyzed by silver staining. No common RNA compo-
nent was detected, suggesting TIF1b is not complexed
with specific RNA (data not shown).
Confirmation of the 120 kD protein as TIF1b
The identity of the 120 kD protein immunoprecipitated
by human sera as TIF1b was confirmed by IP-WB
(Figure 2A). The proteins immunoprecipitated by
human autoimmune sera were recognized by mAb to
TIF1b, confirming the identity of the protein.
Antigen-capture ELISA using mouse anti TIF1b mAb
was also performed using serially diluted anti-TIF1b posi-
tive sera (Figure 2B). All four anti-TIF1b positive sera
were positive in ELISA in titers up to 1:12,500 to 1:
312,500. Control sera including anti-TIF1g or anti-Mi-2
positive sera and NHS, were all negative.
Western blot using affinity purified TIF1b
Strips of nitrocellulose filter with TIF1b affinity-purified by
mAb were probed with mouse mAb anti-TIF1b and
human autoimmune sera. Mouse mAb strongly reacted
with the purified TIF1b protein; however, human autoim-
mune sera were negative when the western blot was devel-
oped using SuperSignal West Pico. Only the serum from
case one was very weakly positive when developed using
more sensitive SuperSignal West Femto (Figure 2C).
Immunofluorescence staining of anti-TIF1b positive sera
HEp-2 ANA slides were stained with mouse anti-TIF1b
mAb or human sera (Figure 2D). Mouse mAb showed a
fine nuclear speckled pattern sparing the nucleoli and
without chromosomal staining (panel a). Relatively mono-
specific serum from a Japanese patient (case one) showed
a pattern very similar to that of mAb (panel b). Other sera
(cases two to four) also showed a fine speckled nuclear
staining pattern (panels c-e); however, one serum (case
three) also had large nuclear speckles (panel d). A serum
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Figure 1 Immunoprecipitation using 35S-methionine labeled K562 cell extract. A. 8% SDS-PAGE. 35S-methionine labeled K562 cell extract
was immunoprecipitated as follows: Anti-TIF1b mAb; lanes 1 to 4, anti-TIF1b positive human sera; 20% 2, 20% loading of prototype serum in
lane 2; PL-12, p155/140, NHS, normal human serum; Mi-2, reference serum for each specificity. Positions of TIF1b, Su/Ago2, Ro 60, U1snRNP A
(U1-A), and molecular weight markers are shown on the left. White arrowheads indicate PL-12 (lane PL-12) and p155 (TIF1g) and p140 (TIF1a)
(lane p155/140). B. 12.5% SDS-PAGE. Sequential sera from case two were tested by immunoprecipitation. Positions of components of UsnRNPs,
TIF1b, and Ro-60 and molecular weight markers are shown. NHS, normal human serum; Sm, U1, anti-Sm and anti-U1RNP reference serum,
respectively; TIF, transcription intermediary factor.
Table 1 Clinical features of patients with anti-TIF1b autoantibodies.
1 2 3 4
Diagnosis DM UCTD DM DM
Symmetrical muscle weakness P N P Y
Muscle biopsy Y ND ND NA
Elevated muscle enzyme Y Y Y Y
EMG myopathic pattern myopathic pattern myopathic pattern NA
Dermatologic features Y (G) N P (S) Y (G, H, S)
Malignancy N Y N N
Interstitial lung disease N N N N
Dysphagia Y N N N
Raynaud’s phenomenon N N N N
Arthritis N Y N N
CPK (U/L) initial
/after Tx (lowest)
654
167
341
239
314 2414
Initial Tx none PSL 10 mg PSL 40 mg PSL 50 mg
HCQ 200 mg
NSAIDs
HCQ 200 mg MTX 20 mg/w
HCQ 150 mg
Response to Tx NA good good good
Other autoantibodies Ro, Su, U1RNP (Sm) Mi-2, Su
ELISA (RP) TIF1a - - + -
TIF1b + + - -
TIF1g - - - -
antigen-capture ELISA
TIF1a - - - -
TIF1b + + weak + weak +
DM, dermatomyositis; ELISA, enzyme-linked immunosorbent assay; EMG, electromyogram; G, Gottron; H, heliotrope; HCQ, hydroxychloroquine; MTX,
methotrexate; N, no; NA, not available; ND, not done; NSAIDs, non-steroid anti-inflammatory drugs; P, possible; PSL, prednisolone; RP, recombinant protein; S,
shawl sign; TIF, transcription intermediary factor; Tx, treatment; UCTD, undifferentiated connective tissue disease; Y, yes;
Satoh et al. Arthritis Research & Therapy 2012, 14:R79
http://arthritis-research.com/content/14/2/R79
Page 4 of 8
with coexisting anti-Mi-2 (case four) also had fine
speckled nuclear staining (panel e).
Clinical manifestations of patients with anti-TIF1b
antibodies
Clinical features of anti-TIF1b antibody positive cases are
summarized in Table 1. All four were women, three with a
diagnosis of DM and one classified as undifferentiated
connective tissue disease (UCTD) with elevated creatine
phosphokinase (CPK) but without significant muscle
symptoms. Thus, anti-TIF1b was found in 3/130 DM (1/
35 Americans, 1/23 Japanese, 1/56 Mexicans) but 0/92
PM and none in SLE, SSc, or other conditions, suggesting
that this specificity may be closely associated with DM,
similar to antibodies to p155/140 (TIF1g/a). The Japanese
DM patient (case one) had elevated CPK (654 IU/L), mild
muscle weakness, myalgia, a positive muscle biopsy and
electromyogram (EMG); however, her myopathy resolved
without treatment. The UCTD case (case two) also had
elevated muscle enzymes, but muscle symptoms were not
clear. Moreover, she had leukopenia, lymphopenia and
autoimmune hemolytic anemia. This case also had a his-
tory of colon cancer (at age 41), cervical squamous meta-
plasia and fibroid tumors of the uterus. Two American
patients (cases two and three) had mildly elevated levels of
CPK (approximately 300 IU/L) that were controlled with
low to moderate doses of steroids. The Mexican case also
had high CPK but responded well to initial treatment.
Discussion
In the present study, a 120 kD protein recognized by sera
from four patients with DM or UCTD was identified as
TIF1b based on mass spectrometric analysis and
immunological confirmation, and it is closely related to a
known cancer-associated DM autoantigen p155/140
(TIF1g/a). Since the mobility of TIF1b in SDS-PAGE is
identical to that of PL-12 (Figure 1), approximately 120
kD protein bands seen in IP will need to be cautiously
interpreted. However, TIF1b and PL-12 have distinctive
immunofluorescence patterns, which should help to dif-
ferentiate the specificities. Anti-TIF1b produces a fine
nuclear speckled pattern (Figure 2D) while anti-PL-12
gives a cytoplasmic pattern [24].
TIF1a, TIF1b, and TIF1g belong to the TIF family of
transcription cofactors and are part of a tripartite motif
superfamily (TRIM24, 28, and 33, respectively) [23].
TIF1b/TRIM28, also known as Kruppel-associated box
(KRAB)-associated protein 1 (KAP1), is a multi-functional
protein involved in gene silencing, cell growth and differen-
tiation, pluripotency, neoplastic transformation, apoptosis,
DNA repair and the maintenance of genomic integrity
[25]. A striking association of anti-p155/140 with cancer-
associated DM has been described in several reports from
the US [5], UK [7], Spain [9], Japan [6,8,10,11], and Korea
[26] (reviewed in [9]), however, their association does not
seem to apply to children [7] or young adults [11]. A
Japanese PM/DM study that has just been published iden-
tified p140 as TIF1a and confirmed the p155 as TIF1g
[11]. In addition, seven cases with anti-TIF1b, four with
anti-TIF1a and g and two with anti-TIF1g have been
reported. It should be noted that in contrast to a previous
study limited to PM/DM [11], anti-TIF1b antibodies were
screened in 2,356 patients with various diagnoses in the
present study, yet it was primarily associated with DM.
Both studies suggest that anti-TIF1b is much less prevalent
than anti-p155/140. Six of their 77 anti-p155/140 positive
Figure 2 Characterization of human anti-TIF1b positive sera. A. IP-western blot. Extract from 5 × 106 K562 cells was immunoprecipitated by
mouse anti-TIF1b mAb, human anti-TIF1b positive sera (lanes 1 to 3 correspond to case 1 to 3, case 3 is a weakly positive sample), human anti-
p155/140 (TIF1-g/a) positive serum, or normal human serum (NHS). Purified proteins were fractionated by 8% SDS-PAGE, transferred to
nitrocellulose filter and probed with mouse anti-TIF1b mAb. Only 1/10 amount of immunoprecipitates was loaded for mAb, case 1, and 2 in
order to obtain more comparable signals to case 3. B. Anti-TIF1b antigen-capture ELISA. Four human anti-TIF1b positive sera (left) and controls
(right, 3 anti-TIF1-g, 3 anti-Mi-2, and 2 normal human sera, NHS) were serially diluted from 1:500 and tested by antigen-capture ELISA. C. Western
blot. D. Immunofluorescence staining of HEp-2 cells. HEp-2 slides were stained with anti-TIF1b mouse monoclonal antibodies (a), anti-TIF1b
antibody positive human autoimmune sera (b-e), or normal human serum (f). Serum dilution 1: 80; anti-TIF1b mAb, 1 μg/ml. ELISA, enzyme-
linked immunosorbent assay; NHS, normal human serum; TIF, transcription intermediary factor.
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sera were also positive for anti-TIF1b [11] whereas none of
our 23 anti-p155/140 were anti-TIF1b positive (data not
shown). Although the difference observed between the two
studies is not statistically significant, it is possible that
coexisting patterns of autoantibodies to TIF family proteins
are affected by genetic and/or environmental factors, selec-
tion bias (dermatology versus rheumatology clinic, for
example) and other factors.
It has been shown that these TIF1 family proteins inter-
act and work synergistically to suppress the development
of malignancy in human and mouse models [23,27]. TIF1b
is overexpressed in various types of cancer tissues [28] and
is associated with progression or metastasis of the cancer
[29,30]. It would not be surprising if the production of
anti-TIF1b is also linked with cancer-associated DM as
overexpression and modification of self-protein may trig-
ger an autoimmune response. In the present study, one
case with anti-TIF1b had a history of colon cancer, squa-
mous metaplasia in a cervical smear and fibroid tumors of
the uterus, but malignancy was not recorded in the other
three cases, possibly due in part to a short follow-up per-
iod. A recent study [11] showed two of seven cases with
anti-TIF1b had malignancy, possibly less frequently than
anti-p155/140 positive cases.
In the case of the classic tumor suppressor gene p53,
mutation and accumulation of p53 leads to the develop-
ment of cancer as well as autoantibodies to p53, which is
considered a result of broken immunological tolerance
due in part to mutated p53 [31]. As TIF family proteins
are known tumor suppressors [23,27] and are overex-
pressed in certain cancer tissues [28-30], a possible rela-
tionship between the development of autoantibodies to
TIF and cancer may be explained by a similar mechanism.
In this scenario, a mutation of TIF occurs as a primary
event and triggers an autoimmune response against TIF,
while cancer would develop due to the failed tumor sup-
pressive activity of TIF. Further studies are necessary to
determine whether anti-TIF1b has a strong association
with cancer similar to anti-TIF-g and whether TIF muta-
tions are the primary event.
Alternative or additional mechanisms of anti-TIF1b pro-
duction may be hypothesized based on the role of TIF1b
in viral infections. TIF1b/KAP1 has been shown to play a
critical role in controlling replication of Epstein-Barr virus
[32], expression of murine endogenous retroviruses
[33,34], latency regulation of Kaposi’s sarcoma-associated
herpesvirus (KSHV) [35], and replication of human papil-
lomaviruses [36]. In this scenario, TIF1b would interact
with viral proteins and the putative viral-self protein com-
plex may trigger autoantibodies to TIF1b, similar to the
induction of anti-p53 by a complex of viral simian virus
40 T protein and self p53 protein [37]. Association of
virus and myositis autoantibody production has been sug-
gested to occur by various pathways, including viral RNA
interaction with aminoacyl tRNA synthetase and molecu-
lar mimicry of viral protein and autoantigens [38,39].
More recently, a target antigen of anti-CADM140 was
identified as an intracellular viral RNA receptor, mela-
noma differentiation-associated gene 5 (MDA5) [13].
Thus, any of these mechanisms may also be involved.
Conclusions
In summary, anti-TIF1b has been characterized as autoan-
tibodies associated with DM with a mild form of myopa-
thy without lung involvement. TIF1b is a multifunctional
protein closely related to the known cancer-associated
DM autoantigen p155/140 (TIF1g/a) involved in suppres-
sion of malignancy as well as viral replication [23,27]. Both
mutation of TIF1b and its interaction with viruses make
an attractive hypothesis for the mechanism of production
of autoantibodies to TIF1b. Future studies should verify an
association of anti-TIF1b with malignancy and clarify
mechanisms of its production.
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